RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cosmo Pharmaceuticals ROCE 2024

Cosmo Pharmaceuticals ROCE

0

Cosmo Pharmaceuticals Dividend yield

1.46 %

Ticker

COPN.SW

ISIN

NL0011832936

WKN

A2AJ68

In 2024, Cosmo Pharmaceuticals's return on capital employed (ROCE) was 0, a -100% increase from the 0.06 ROCE in the previous year.

Cosmo Pharmaceuticals Aktienanalyse

What does Cosmo Pharmaceuticals do?

Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Cosmo Pharmaceuticals's Return on Capital Employed (ROCE)

Cosmo Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cosmo Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cosmo Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cosmo Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cosmo Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of Cosmo Pharmaceuticals this year?

The ROCE of Cosmo Pharmaceuticals is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Cosmo Pharmaceuticals developed compared to the previous year?

The ROCE of Cosmo Pharmaceuticals has increased by -100% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Cosmo Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Cosmo Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Cosmo Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Cosmo Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Cosmo Pharmaceuticals impact the company?

An increase in the ROCE of Cosmo Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Cosmo Pharmaceuticals affect the company?

A decrease in ROCE of Cosmo Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Cosmo Pharmaceuticals?

Some factors that can affect Cosmo Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Cosmo Pharmaceuticals so important for investors?

The ROCE of Cosmo Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Cosmo Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Cosmo Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Cosmo Pharmaceuticals pay?

Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.46 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.

What is the dividend yield of Cosmo Pharmaceuticals?

The current dividend yield of Cosmo Pharmaceuticals is 1.46 %.

When does Cosmo Pharmaceuticals pay dividends?

Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of June, July, June, June.

How secure is the dividend of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals paid dividends every year for the past 8 years.

What is the dividend of Cosmo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.46 %.

In which sector is Cosmo Pharmaceuticals located?

Cosmo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cosmo Pharmaceuticals from 5/30/2024 amounting to 2.17 EUR, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Cosmo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Cosmo Pharmaceuticals in the year 2023?

In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.

In which currency does Cosmo Pharmaceuticals pay out the dividend?

The dividends of Cosmo Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cosmo Pharmaceuticals

Our stock analysis for Cosmo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.